According to some, 2015 is the year of the future. And that tongue-in-cheek superlative (derived from the 1989 movie, Back to the Future Part II) may be deserved, at least in the field of medicine. Earlier this month, MSDF covered a story about optimistic results from the phase 2 “HALT-MS” trial testing hematopoietic cell transplantation (HCT) in relapsing-remitting multiple sclerosis (RRMS) patients (Nash et al., 2014 . More recently, another research team published results from a separate phase 2 trial testing a different HCT method that had similar results to HALT-MS (Burt et al., 2015). It seems in 2015, the question isn’t “Can we do this?” but “How should we do this?”
The results
— CLICK here to continue reading
.